Descending
|
11/10/2009 MJFF Awards $2.2 Million to Four Clinical Trials for New Parkinson's Interventions
Funded projects focus on alleviating complications of PD treatment and addressing patients' unmet needs.
10/14/2009 Michael J. Fox Foundation Announces Support for LRRK2 Cohort Studies
The Michael J. Fox Foundation announced $5.2 million in support for two studies defining the clinical presentation of PD in two populations in which LRRK2 gene mutations are associated with a significantly increased risk of PD.
The researchers have identified two drug-like molecules that, when given systematically in a pre-clinical model of Parkinson’s disease, reduce PD symptoms by acting on a specific glutamate receptor in the brain called the metabotropic glutamate receptor, or mGluR4. Also available: A News in Context Q&A with Dr. Conn on the significance of the finding, and next steps.
09/24/2009 MJFF Announces Status as a Registered Canadian Charity
MJFF is now a registered, tax-exempt charity in Canada. The official launch was celebrated with a day of events in Toronto.
The funding, aimed at to successfully translating neurotrophic factor advances from pre-clinical and early-phase clinical work into a practical, patient-relevant treatment for Parkinson’s disease, will be awarded under a new directed LEAPS (Linked Efforts to Accelerate Parkinson’s Solutions) initiative.
Funding is open to academic and industry researchers through the Foundation’s 2010 Pipeline Programs.
Funded investigations aim to push forward novel neuroprotective and improved symptomatic therapies as well as new strategies for addressing complications of treatment.
The Michael J. Fox Foundation for Parkinson’s Research announced approximately $2.1 million in total funding to 10 research teams working to validate therapeutic targets for Parkinson’s disease.
07/08/2009 Michael J. Fox Foundation to Fund Continuing Open-label Study of CERE-120 Safety and Efficacy
The Michael J. Fox Foundation has signed on to fund the long-term, open-label analysis of data from Ceregene, Inc.’s Phase 2 trial of CERE-120, a gene therapy approach to deliver trophic factor neurturin to the brains of Parkinson’s patients. The funding will allow Ceregene to collect and analyze data from trial enrollees for another 48 months.
As of mid-2009, The Michael J. Fox Foundation for Parkinson’s Research has already funded over $1 million in high-risk, high-reward approaches to Parkinson’s therapeutic development through its groundbreaking Rapid Response Innovation Awards.
06/01/2009 MJFF Announces Launch of PD Online Research
The Michael J. Fox Foundation announced the launch of a new Web-based community to increase collaboration and resource-sharing in the global PD scientific community.
The Michael J. Fox Foundation's fourth round of biomarker funding aims to continue stimulating discovery of new disease and drug biomarkers.
The Michael J. Fox Foundation for Parkinson’s Research will award up to $6.5 million in total funding under three Critical Challenges research programs designed to accelerate solutions to some of the most difficult hurdles standing in the way of breakthrough therapeutics for PD.
03/27/2009 Michael J. Fox Foundation Awards $2.1 Million to Improve Drug Delivery in Parkinson's Disease
The Michael J. Fox Foundation announced that it has awarded approximately $2.1 million total to seven research teams working to improve drug delivery for Parkinson’s disease.
03/17/2009 Welcome, Baseball Fans! Michael J. Fox Foundation Chosen as One of Fox Sports Supports 2009 Partners
The first FOX Sports Supports campaign was launched in 2008 to increase awareness and raise funds for worthy health-related charities. After a highly successful inaugural year working, the program returns for a second campaign with four new inspiring organizations, including The Michael J. Fox Foundation.
The Michael J. Fox Foundation for Parkinson’s Research seeks applications from industry researchers under its $5-million Therapeutics Development Initiative (TDI). The Foundation also announced that, going forward, TDI will be launched bi-annually.
Limited-time special offer will make 23andMe personal genetics service available to people with PD for $25 instead of standard $399
Read statements from Michael J. Fox and Katie Hood on President Obama's overturn of the ban on federal funding for embryonic stem cell research -- as well as a News in Context discussing the implications for Parkinson's research.
02/18/2009 MJFF Awards $1.9 Million for Development of Non-invasive Neuroimaging Techniques in Living Brain
The Michael J. Fox Foundation for Parkinson’s Research awarded approximately $1.9 million total to six teams working to develop neuroimaging technologies that would allow scientists to non-invasively visualize the clumping of the alpha-synuclein protein in the living human brain.
The Michael J. Fox Foundation for Parkinson’s Research has awarded $2.5 million total for seven Parkinson’s drug development projects. The funding was awarded under a special, one-time academic funding track of the Foundation’s industry-focused Therapeutics Development Initiative.
01/12/2009 Michael J. Fox Foundation Awards $2.9 Million for Two New Parkinson's Disease Clinical Trials
The Michael J. Fox Foundation for Parkinson’s Research awarded about $2.9 million total for two clinical studies that will test drugs already approved in other disease indications for potential efficacy against Parkinson’s disease.
01/06/2009 MJFF Awards $2.7 Million to Four Industry Teams for Pre-clinical Parkinson's Disease Research
The Michael J. Fox Foundation awarded a total of $2.7 million to four industry research teams for pre-clinical research on potential new treatments for Parkinson’s disease.
